Improving psychostimulant adherence in children with ADHD

Expert Review of Neurotherapeutics

Volumn 8, Issue 10, 2008, Pages 1563-1571

  Charach, Alice ^a,b,c   Gajaria, Amy ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Child Health Evaluative Sciences   (Canada)

Author keywords

Attention deficit hyperactivity disorder; Patient compliance; Psychostimulant; Treatment refusal

Indexed keywords

PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CHILD BEHAVIOR; CHILDHOOD DISEASE; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG USE; DRUG WITHDRAWAL; FAMILY RELATION; HUMAN; HYPERACTIVITY; IMPULSIVENESS; LONG TERM CARE; PATIENT COMPLIANCE; REVIEW; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE;

EID: 54249131158     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.10.1563     Document Type: Review

References (53)

1. Johnston C, Seipp C, Hommersen P, Hoza B, Fine S. Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions. Child Care Health Dev. 31(6), 669-677 (2005).
2. Dosreis S, Zito JM, Safer DJ, Soeken KL, Mitchell JW Jr, Ellwood LC. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J. Dev. Behav. Pediatr. 24(3), 155-162 (2003).
3. Gau SS, Chen SJ, Chou WJ et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J. Clin. Psychiatry 69(1), 131-140 (2008).
4. The MTA Cooperative Group, National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113(4), 762-769 (2004).
5. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J. Am. Acad. Child Adolesc. Psychiatry 43(5), 559-567 (2004).
6. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J. Dev. Behav. Pediatr. 27(1), 1-10 (2006).
7. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. J. Am. Acad. Child Adolesc. Psychiatry 39(8), 975-994 (2000).
8. dosReis S, Butz A, Lipkin PH, Anixt JS, Weiner CL, Chernoff R. Attitudes about stimulant medication for attention-deficit/hyperactivity disorder among African American families in an inner city community. J. Behav. Health Serv. Res. 33(4), 423-430 (2006).
9. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am. J. Psychiatry 165(5), 597-603 (2008).
10. Mannuzza S, Klein RG, Truong NL et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am. J. Psychiatry 165(5), 604-609 (2008).
11. Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv. Rev. Psychiatry 9(5), 223-233 (2001).
12. Hansen DL, Hansen EH. Caught in a balancing act: parents' dilemmas regarding their ADHD child's treatment with stimulant medication. Qual. Health Res. 16(9), 1267-1285 (2006).
13. Singh I. Will the "real boy" please behave: dosing dilemmas for parents of boys with ADHD. Am. J. Bioeth. 5(3), 34-47 (2005).
14. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. [see comment]. J. Manag. Care Pharm. 10(2), 122-129 (2004).
15. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 159(6), 572-578 (2005). Erratum appears in Arch. Pediatr. Adolesc. Med. 159(9), 875 (2005).
16. Miller AR, Lalonde CE, McGrail KM. Children's persistence with methylphenidate therapy: a population-based study. Can. J. Psychiatry 49(11) (2004).
17. Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J. Atten. Disord. 11(2), 157-166 (2007).
18. Vitiello B, Severe JB, Greenhill LL et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J. Am. Acad. Child Adolesc. Psychiatry 40(2), 188-196 (2001).
19. Wilens T, Pelham W, Stein M et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from long-term open label study. J. Am. Acad. Child Adolesc. Psychiatry 42, 424-433 (2003).
20. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J. Child Adolesc. Psychopharmacol. 16(3), 286-297 (2006).
21. Schachar R, Jadad AR, Gauld M et al. Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Can. J. Psychiatry 47(4), 337-348 (2002).
22. Swanson JM, Hinshaw SP, Arnold LE et al. Secondary evaluations of the MTA 36-month outcomes: propensity score and growth mixture model analyses. J. Am. Acad. Child Adolesc. Psychiatry 46(8), 1003-1014 (2007).
23. Rieppi R, Greenhill LL, Ford RE et al. Socioeconomic status as a moderator of ADHD treatment outcomes. J. Am. Acad. Child Adolesc. Psychiatry 41(3), 269-277 (2002).
24. Leslie LK, Plemmons D, Monn AR, Palinkas LA. Investigating ADHD treatment trajectories: listening to families' stories about medication use. J. Dev. Behav. Pediatr. 28(3), 179-188 (2007).
25. Jensen PS, Arnold LE, Swanson JM et al. 3-year follow-up of the NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry 46(8), 989-1002 (2007).
26. Singh I. Boys will be boys: fathers' perspectives on ADHD symptoms, diagnosis, and drug treatment. Harv. Rev. Psychiatry 11(6), 308-316 (2003).
27. Meaux JB, Hester C, Smith B, Shoptaw A. Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J. Spec. Pediatr. Nurs. 11(4), 214-226 (2006).
28. Charach A, Skyba A, Cook L, Antle BJ. Using stimulant medication for children with ADHD: what do parents say? A brief report. J. Can. Acad. Child Adolesc. Psychiatry 15(2), 75-83 (2006).
29. Bussing R, Gary FA, Mills TL, Garvan CW. Parental explanatory models of ADHD: gender and cultural variations. Soc. Psychiatry Psychiatr. Epidemiol. 38(10), 563-575 (2003).
30. Bussing R, Koro-Ljungberg ME, Gary F, Mason DM, Garvan CW. Exploring help-seeking for ADHD symptoms: a mixed-methods approach. Harv. Rev. Psychiatry 13(2), 85-101 (2005).
31. Corkum P, Rimer P, Schachar R. Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial. Can. J. Psychiatry 44(10), 1043-1048 (1999).
32. Johnston C, Hommersen P, Seipp C. Acceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristics. Behav. Ther. 39, 22-32 (2008).
33. Bull C, Whelan T. Parental schemata in the management of children with attention deficit-hyperactivity disorder. Qual. Health Res. 16(5), 664-678 (2006).
34. Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J. Am. Acad. Child Adolesc. Psychiatry 36(6), 754-763 (1997).
35. Pliszka SR, Lopez M, Crismon ML et al. A feasibility study of the children's medication algorithm project (CMAP) algorithm for the treatment of ADHD. J. Am. Acad. Child Adolesc. Psychiatry 42(3), 279-287 (2003).
36. Cheng J, Walter EC. Nonadherence in Pediatrics in Patient Treatment Adherence Concepts, Interventions, and Measurement. Bosworth HB, Oddone EZ, Weinberger M (Eds). Lawrence Erlbaum Associates, Inc., Mahwah, NJ, USA, 239-273 (2006).
37. Creswell J. Qualitative Inquiry and Research Design. Sage Publications, CA, USA (1998).
38. Swanson JM, Elliott GR, Greenhill LL et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J. Am. Acad. Child Adolesc. Psychiatry 46(8), 1015-1027 (2007).
39. Frey M, Naar-King S. Measurement corner. The challenge of measuring adherence in children and adolescents. J. Child Fam. Nurs. 4(4), 296-300 (2001).
40. Charach A, Gajaria A, Skyba A, Chen S. Documenting adherence to psychostimulants in children with ADHD. J. Can. Acad. Child Adolesc. Psychiatry 17(3), 131-136 (2008).
41. Becker M, Maiman L. Sociobehavioral determinants of compliance with health and medical care recommendations. Med. Care 13, 10-24 (1975).
42. Ajzen I, Fishbein M. Understanding Attitudes and Predicting Social Behavior. Prentice Hall, NJ, USA (1980).
43. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am. Psychol. 47, 1102-1114 (1992).
44. Pescosolido BA. Beyond rational choice: the social dynamics of how people seek help. Am. J. Sociol. 97, 1096-1138 (1992).
45. Charach A, Volpe T, Boydell KM, Gearing RE. A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv. Rev. Psychiatry 16(2), 126-135 (2008).
46. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114(5), e541-e547 (2004).
47. Reach G. Role of habit in adherence to medical treatment. Diabet. Med. 22, 415-420 (2005).
48. Greenhill LL, Pliszka S, Dulcan MK et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry 41(Suppl. 2), 26S-49S (2002).
49. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 108(4), 1033-1044 (2001).
50. Wolraich ML, Wibbelsman CJ, Brown TE. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 115(6), 1734-1746 (2005).
51. Harris RP, Helfand M, Woolf SH et al. Current methods of the U.S. Preventative Services Task Force: a review of the process. Am. J. Prev. Med. 20(Suppl. 3), 21-35 (2001).
52. Guion LA. Triangulation: Establishing the Validity of Qualitative Studies. Institute of Food and Agricultural Sciences, Gainsville, Florida, University of Florida, FL, USA (2002).
53. Law M, Stewart D, Letts L, Pollock N, Bosch J, Westmorland M. Critical Review Form - Qualitative Studies. McMaster University, Hamilton, ON, Canada (1998).